General Information of Drug Transporter (DT)
DT ID	DTD0017 Transporter Info
Gene Name	ABCC6
Protein Name	Multidrug resistance-associated protein 6
Gene ID	368
UniProt ID	O95255
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs2238472
Site of GPD	chr16:16157742 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	T=0.1813/908 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Docetaxel	Drug Info	Prostatic Neoplasm	Correlated with the increased toxicity risk in patients (compare with Allele T)		[ 1]
Thalidomide	Drug Info	Prostatic Neoplasm	Correlated with the increased toxicity risk in patients (compare with Allele T)		[ 1]
Docetaxel	N.A.	Colorectal Neoplasms	Allele C is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele T.		[ 1]
Thalidomide	N.A.	Colorectal Neoplasms	Allele C is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele T.		[ 1]
Docetaxel	N.A.	Prostatic Neoplasms	Allele C is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele T.		[ 1]
Thalidomide	N.A.	Prostatic Neoplasms	Allele C is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele T.		[ 1]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Docetaxel	N.A.	Prostatic Neoplasms	Patients with the CC genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.		[ 1]
Thalidomide	N.A.	Prostatic Neoplasms	Patients with the CC genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.		[ 1]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Docetaxel	N.A.	Prostatic Neoplasms	Patients with the CT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.		[ 1]
Thalidomide	N.A.	Prostatic Neoplasms	Patients with the CT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.		[ 1]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Docetaxel	N.A.	Prostatic Neoplasms	Patients with the TT genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.		[ 1]
Thalidomide	N.A.	Prostatic Neoplasms	Patients with the TT genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.		[ 1]
Genetic Polymorphism	rs12929610
Site of GPD	chr16:16197770 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.4280/847 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Drugs For Treatment Of Tuberculosis	N.A.	Toxic Liver Disease	Allele G is not associated with risk of Toxic liver disease due to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to allele A.		[ 2]
Genetic Polymorphism	rs4781732
Site of GPD	chr16:16168715 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.7380/1460 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Drugs For Treatment Of Tuberculosis	N.A.	Toxic Liver Disease	Allele A is not associated with risk of Toxic liver disease due to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to allele G.		[ 2]
Genetic Polymorphism	rs8058694
Site of GPD	chr16:16185006 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>T
Minor Allele Frequency	G=0.6610/1308 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Drugs For Treatment Of Tuberculosis	N.A.	Toxic Liver Disease	Allele T is not associated with risk of Toxic liver disease due to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to allele G.		[ 2]
Genetic Polymorphism	rs12935089
Site of GPD	chr16:16198271 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	C=0.6800/1345 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Drugs For Treatment Of Tuberculosis	N.A.	Toxic Liver Disease	Allele T is not associated with risk of Toxic liver disease due to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to allele C.		[ 2]
References
1	A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform. Pharmacogenomics J. 2010 Jun;10(3):191-9.
2	Association of ABCC Gene Polymorphism With Susceptibility to Antituberculosis Drug-Induced Hepatotoxicity in Western Han Patients With Tuberculosis. J Clin Pharmacol. 2020 Mar;60(3):361-368.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.